Cobalis Corp. Reports Phase III Trial Results for PreHistin™ in Seasonal Allergic Rhinitis Has Inconclusive Outcome

IRVINE, Calif.--(BUSINESS WIRE)--Cobalis Corp. (OTCBB:CLSC), a pharmaceutical development company specializing in anti-allergy medications, today reported preliminary top-line results from two Phase III clinical trials for its drug PreHistin™ in patients with moderate to moderately severe seasonal allergic rhinitis, commonly known as hay fever. The trials showed very low symptom levels in both placebo and PreHistin-treated patient groups, thereby leaving no room to demonstrate a meaningful drug effect.